Investigating Immune Mechanisms in Atopic Eczema
This trial is active, not recruiting.
|Treatments||skin biopsy, skin suction blister, mantoux test|
|Sponsor||University College, London|
|Start date||May 2014|
|End date||May 2017|
|Trial size||140 participants|
|Trial identifier||NCT02102841, 13/0410, 14/LO/0243|
The aim of this study is to investigate the mechanisms behind the immune dysfunction that occurs in atopic eczema (or atopic dermatitis).
|Intervention model||parallel assignment|
|Primary purpose||basic science|
Number of regulatory T cells in lesional skin of atopic dermatitis patients compared to healthy volunteers
time frame: Up to 14 days
Male or female participants at least 18 years old.
Inclusion Criteria: - History of atopic dermatitis (according to United Kingdom Working Party's diagnostic criteria) - Previous Bacillus Calmette-Guerin vaccination Exclusion Criteria: - Unable to give written informed consent - Previous history of hypersensitivity to local anaesthetic (for skin biopsy) or tuberculin PPD (for skin test) - Pregnancy or breast feeding - History of tuberculosis - Recent infection or immunisation (within last month) - Known immunodeficiency e.g. HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy - Systemic steroids within the last month or any other immunosuppressive medications (eg. methotrexate, ciclosporin or azathioprine) within the previous 3 months - Phototherapy within the previous 28 days - Treatment with potent topical corticosteroids or tacrolimus ointment within the previous 7 days - Significant co-morbidity (diabetes, renal failure, liver failure, heart failure) - On warfarin or known bleeding disorder - History of neoplasm in last 10 years (not including basal cell carcinoma) - Previous keloid scarring
|Official title||Investigating the Role of Skin Resident T Cells in Atopic Eczema and Responses to Antigen Challenge|
|Principal investigator||Malcolm Rustin, MBBS MRCP MD|
|Description||Atopic eczema is a chronic inflammatory skin disease that affects 15-20% of children and 12% of adults and leads to significant loss of quality of life. It results from a complex interaction of genetic and environmental factors, and is characterised by dysregulation of the cutaneous immune system. Specifically, in the skin of eczema patients there is a persistence of T lymphocytes (a crucial cell involved in regulating the immune system), and an overproduction of certain cytokines (signalling molecules that are essential in producing inflammatory responses). The study intends to investigate the causes of atopic eczema by examining the number, characteristics and function of T lymphocytes in the skin and the blood of eczema patients, as well as the types of cytokine they produce. To achieve this the investigators aim to take skin biopsies, tissue fluid (from induced skin suction blisters) and blood samples from adult eczema patients and healthy controls for analysis. Additionally, in these groups a cutaneous immune response will be initiated by injecting tuberculin protein purified derivative (the Mantoux test) into the skin, to further investigate how the behaviour of T lymphocytes varies between eczema patients and healthy controls. This research is important in view of the high prevalence of atopic eczema in the population. An improved understanding of its causes will hopefully lead to more effective treatments for this condition in future.|
Call for more information